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Transient Myocardial Thickening in Cats Associated with Heart
Failure
J. Novo Matos , N. Pereira, T. Glaus, L. Wilkie, K. Borgeat, J. Loureiro, J. Silva, V. Law, A. Kranjc,
D.J. Connolly, and V. Luis Fuentes
Background: Cats with hypertrophic cardiomyopathy (HCM) and congestive heart failure (CHF) can have resolution of
both left ventricular hypertrophy and CHF.
Objectives: To describe the clinical characteristics of cats with transient myocardial thickening (TMT) and CHF com-
pared with a control population of cats without resolution of HCM.
Animals: A total of 21 cats with TMT, 21 cats with HCM.
Methods: Retrospective study. Clinical records at 4 veterinary centers were searched for TMT cases and a control group
of cats with HCM and CHF. TMT was deﬁned as initial maximal left ventricular wall thickness (LVWT) ≥6 mm with left-
sided CHF, with subsequent resolution of CHF, reduction in left atrium/aorta (LA/Ao), and LVWT<5.5 mm. HCM was
deﬁned as persistent LVWT ≥6 mm.
Results: Cats with TMT were younger (2 [0.4–11.4] years) than cats with HCM (8 [1.6–14] years) (P < 0.0001), and ante-
cedent events were more common (15/21 versus 6/21, respectively) (P = 0.01). In cats with TMT, LVWT normalized from 6.8
[6.0–9.7] mm to 4.8 [2.8–5.3] mm and LA/Ao decreased from 1.8 [1.6–2.3] to 1.45 [1.2–1.7] after a mean interval of 3.3 (95%
CI: 1.8–4.7) months. CHF recurred in 1 of 21 TMT and 15 of 21 cats with HCM. Cardiac treatment was discontinued in 20
of 21 cats with TMT and 0 of 21 HCM cats. All cats with TMT survived, whereas 8 of 19 cats with HCM died during the
study period.
Conclusions and Clinical Importance: TMT occurs in younger cats, and antecedent events are common. The prognosis is
better in cats with CHF associated with TMT than HCM.
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A hypertrophic cardiomyopathy (HCM) phenotypeis characterized by increased left ventricular wall
thickness (LVWT) in the absence of abnormal loading
conditions capable of producing a similar degree of ven-
tricular thickening.1,2 Myocardial wall thickness depends
on 3 elements: the number of myocytes, myocyte size,
and the volume of the interstitial space.3,4 In HCM, the
increased LVWT is mediated by an increase in mass of
individual myocytes and interstitial ﬁbrous connective
tissue,5 with the former being the most important
component.3,4,6 Other diseases can mimic HCM by caus-
ing an increase in LVWT that is not due to myocyte
hypertrophy or hyperplasia, such as intracellular accu-
mulation of metabolic products (storage diseases) or
interstitial inﬁltration of proteins, cells or ﬂuid, such as
in amyloidosis or myocarditis.2,7 These conditions repre-
sent up to 10% of all adult human cases with an HCM
phenotype.2 In cats, an HCM phenotype has been
described with endocrine disorders, such as hyperthy-
roidism or acromegaly, dehydration (pseudohypertro-
phy), and inﬁltrative disease (cardiac lymphoma).8–11 It
is not known whether metabolic diseases or inﬂammatory
disease are responsible for the abnormal phenotype seen
in some cats diagnosed with HCM.
Cats with HCM and congestive heart failure (CHF)
are generally reported to have a poor prognosis.12,13 We
were aware of anecdotal reports of cats presenting with
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CMR cardiac magnetic resonance
cTnI cardiac troponin I
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LVFS% left ventricle fractional shortening
LVIDd left ventricular internal dimension in diastole
LVWT left ventricular wall thickness
RPLA right parasternal long-axis view
RPSA right parasternal short-axis view
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HCM and CHF that appeared to have a good progno-
sis, and a longitudinal echocardiographic study con-
ducted by one of the authors (LW) conﬁrmed that in
some cats, apparent left ventricular hypertrophy had
resolved by subsequent echocardiographic examinations
(unpublished data). Furthermore, it has been suggested
that cats with this clinical course are often young and
have a history of an antecedent event, such as general
anesthesia for neutering within days of presentation
with CHF.14 As reverse remodeling with normalization
of cardiac structure and function is not an expected
outcome in HCM,15,16 these clinical observations
describe a transient form of myocardial thickening asso-
ciated with CHF in cats. Transient myocardial thicken-
ing (TMT) mimicking HCM has been described in
some forms of acute/fulminant myocarditis in
humans7,17–19 and in atypical cases of stress-induced
(Takotsubo) cardiomyopathy.20–23 In both situations,
the increased LVWT is associated with myocardial
edema.7,20,22–27
The aims of this study were to identify case details of
cats with TMT and CHF from multiple veterinary car-
diologists and describe their clinical and echocardio-
graphic characteristics. Additionally, the clinical and
echocardiographic features of cats with TMT were com-
pared with a control population of cats with HCM and
CHF, to identify characteristics at presentation that
might distinguish cats with TMT from HCM.
Materials and Methods
This study was approved by the Clinical Research Ethical
Review Board of the Royal Veterinary College (URN 2015–1397).
The medical records and echocardiographic database of 4 refer-
ral centers (Royal Veterinary College, Vetsuisse Faculty, Highcroft
Veterinary Referrals, and North Downs Specialists Referrals) were
searched for cats diagnosed as HCM associated with CHF that
showed normalization of LVWT over time. TMT cases were
deﬁned as cats with at least 2 echocardiographic examinations that
had increased LVWT (LVWTd ≥ 6 mm)28,29 and left atrial dilata-
tion (left atrium to aorta ratio [LA/Ao] ≥1.6)30 with left-sided
CHF at presentation but showed subsequent normalization of
LVWT (LVWTd < 5.5 mm) and left atrial size.31 Additionally,
cats with left ventricular fractional shortening <40% or with evi-
dence of focal left ventricular wall thinning with hypokinetic or
dyskinetic myocardial segments at their ﬁnal echocardiographic
examination were excluded from the TMT group.15,16 A control
group of cats with HCM was selected from the medical records
and echocardiographic database at each center involved in the
study. Cats with at least 2 echocardiographic examinations at least
5 months apart with left atrial dilatation (LA/Ao ≥ 1.6) and left-
sided CHF on presentation and persistently increased LVWT
(LVWTd ≥ 6 mm) were selected as control HCM cats. All cats
had CHF documented on thoracic radiographs or echocardiogra-
phy (pleural eﬀusion).
Echocardiographic Data
All echocardiographic examinations were reviewed and remea-
sured at each center by an ECVIM (3 centers) or ACVIM (1 cen-
ter) board-certiﬁed veterinary cardiologist. Echocardiographic
video loops from all cats with TMT submitted to the study (before
and after ventricular thickening resolution) were further reviewed
by 1 observer (JNM) for quality control and to ensure the inclu-
sion criteria were met. Left ventricular free wall and interventricu-
lar septal thicknesses were measured by a leading edge to leading
edge technique from a two-dimensional (2D) right parasternal
long-axis 4- or 5-chambered view (RPLA) and a short-axis view at
the papillary muscle level (RPSA), as the average of the thickest
end-diastolic segment on 3 diﬀerent cardiac cycles in each view
(RPLA and RPSA). End-diastolic frames were deﬁned as the ﬁrst
frame after mitral valve closure in RPLA and as the time point in
the cardiac cycle of greatest left ventricular internal diameter in
RPSA.32 The maximal averaged end-diastolic wall thickness from
both the interventricular septum and left ventricular free wall on
these 2 views was recorded, and the highest value was used for
ﬁnal data analysis, deﬁned as LVWT. All 2D measurements of
cardiac chambers were made by an inner edge to inner edge tech-
nique on the interface between the blood pool and myocardial
wall.33 Left ventricular internal diameter in diastole (LVIDd) was
measured in 2D from a RPLA and RPSA view at the level of the
chordae tendineae, in an end-diastolic frame, on 3 diﬀerent cardiac
cycles in each view. The ratio of the left atrium to aorta (LA/Ao)
was measured in 2D from a short-axis view at the heart base, in
the frame after aortic valve closure (end-ventricular systole).30 Left
atrial (LAFS%) and left ventricular (LVFS%) fractional shorten-
ing were measured by M-Mode from a right parasternal short-axis
at the heart base30 and right parasternal short-axis at the papillary
muscle, respectively. The presence of systolic cranial motion of the
mitral valve (SAM) was assessed on 2D and color Doppler from a
right parasternal long-axis 5-chambered view, as a systolic motion
of the tip of the cranial mitral valve leaﬂet toward the interventric-
ular septum producing turbulent ﬂow in the left ventricular out-
ﬂow tract and mitral regurgitation.34 The presence of spontaneous
echocardiographic contrast (SEC) or a thrombus was assessed
from a RPLA and short-axis views at the heart base.
Exclusion criteria included normal left atrial size (LA/Ao < 1.6)
and the presence of systemic diseases known to aﬀect the cardio-
vascular system, such as hyperthyroidism (all cats >8 years of age
had T4 measured), systemic hypertension (systolic blood pressure
≥160 mmHg),35 diabetes mellitus, and chronic kidney disease
(IRIS Stage >II).
Clinical Data
Additional data collected from the medical and echocardio-
graphic records included age at diagnosis, sex, breed, presenting
clinical signs, heart rate, respiratory rate, temperature, presence of
a murmur, gallop or arrhythmia (and ECG diagnosis when avail-
able), and systolic blood pressure at presentation. In addition, tho-
racic radiographic ﬁndings (ie pulmonary edema, pleural eﬀusion,
or both), number of echocardiographic examinations performed,
treatment, and any clinical pathology results available at presenta-
tion, such as cardiac biomarkers, complete blood count, serum
chemistry, or serology for Toxoplasma gondii, Bartonella henselae,
or FIV/FeLV, were recorded. The medical history of each cat was
carefully evaluated for the presence of antecedent events, deﬁned
as any new medication, general anesthesia, and/or traumatic inci-
dent occurring within 14 days of presentation with CHF.
Outcome Data
Medical records were additionally reviewed for relapses of
CHF, aortic thromboembolism, and cardiac death (death or eutha-
nasia because of signs of CHF and/or aortic thromboembolism, or
sudden death). In cases where treatment was discontinued, the
duration of treatment was determined from the discharge date
from hospital until all cardiac treatment was stopped. At the time
of data collection (September 2015 to September 2016), owners of
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cats identiﬁed with TMT were contacted and invited for follow-up
echocardiographic examinations. All echocardiographic parameters
in cats with TMT at the time of normalization of LVWT (“normal
echo”) were compared with the last available echo (“ﬁnal echo”).
Statistical Analysis
Data were tested for normality graphically and by Shapiro-Wilk
test and for homogeneity of variances by Levene’s test. Between-
group (TMT versus HCM) comparisons were carried out by Fish-
er’s exact for categorical variables and a Mann-Whitney U-test for
continuous variables. A Wilcoxon signed-rank test was used for
within-group comparisons of continuous variables. Data are
reported as median [range], mean (95% conﬁdence interval, 95%
CI), frequency, and percentage. P values <0.05 were considered
statistically signiﬁcant. Statistical analysis was performed by com-
mercially available software.a
Results
Twenty-one TMT cases were identiﬁed in the 4 cen-
ters, and 21 HCM cases were selected as control group.
The frequency of TMT cases seen at the 4 centers ran-
ged between 1 and 4 cases every 2 years. Cats with TMT
were younger (2 [0.4–11.4] years) than cats with HCM (8
[1.6–14] years), P < 0.0001. Males were over-represented
in the HCM group (18 of 21 cats were male versus 10 of
21 males in the TMT group, P = 0.02). Cats with HCM
were also heavier than cats with TMT (P = 0.04) Several
breeds were represented in both groups with equal distri-
bution. Domestic shorthair (DSH) was the most com-
mon breed (10 DSH with TMT and 14 DSH with
HCM). The TMT population also included 4 British
shorthair, 2 Ragdoll, and 2 Domestic Long Hair. The
HCM population also included 2 British Shorthair and
2 Maine Coon. Other breeds included 1 Birman, 1 Rus-
sian Blue and 1 Sphynx in the TMT group and 1
Domestic Long Hair and 1 Exotic Shorthair in the
HCM group. Antecedent events were identiﬁed in 71%
of cats with TMT (15/21) and 29% of cats with HCM
(6/21, P = 0.01). In the TMT group, the most frequent
antecedent event was general anesthesia (7 cats) followed
by road traﬃc accident (2 cats). Anesthesia was per-
formed for ovariohysterectomy (3 cats), and placement
of indwelling urinary catheter, extraction of intestinal
foreign body, tooth extraction, and draining abscess (1
cat each). Other antecedent events included vaccination,
bite wound, pneumonia, fever of unknown origin, fever
with thoracolumbar pain, and abdominal pain with
vomiting (1 cat each). A range of drug combinations
were administered during these events, including antibi-
otics (n = 12), NSAIDs (n = 7), opioids (n = 5), ﬂuids
IV (n = 4), corticosteroids (n = 3), bronchodilators
(n = 2), and antacids (n = 1). In the HCM group, ante-
cedent events included general anesthesia, eye prolapse,
vaccination, abscess, and anorexia (1 cat each). Medica-
tions administered to the HCM group included antibi-
otics (n = 4), corticosteroids (n = 2), antiemetics (n = 2),
and bronchodilators (n = 1). There were no diﬀerences
between groups in the other clinical examination vari-
ables evaluated (Table 1).
Echocardiographic Data
A total of 174 echocardiographic scans were evaluated
from the 42 cats enrolled in the study. Cats with TMT
had a median of 3 [2–7] scans and cats with HCM 4 [2–
9] scans performed during the study period. The time
elapsed between the ﬁrst and last echo was 8 [1.0–57]
months for the whole population and 6 [1–57] months
for cats with TMT and 10 [5–48] months for cats with
HCM. At presentation, cats with TMT had thinner left
ventricular walls than cats with HCM (P = 0.001)
(Table 2, Fig 1). Similarly, at presentation, cats with
TMT had smaller left atria than cats with HCM
(P < 0.0001) (Table 2, Fig 1). In cats with TMT, after a
median period of 3.3 (95% CI: 1.8–4.7) months, the
LVWT normalized (Fig 2). Left atrial size decreased
over time in the TMT group, while it remained severely
dilated in the HCM group (Table 3, Fig 1). Left atrial
fractional shortening was reduced in both groups at pre-
sentation but improved signiﬁcantly in the TMT group
over time (P = 0.001), while it remained markedly
reduced in the HCM group (P = 0.67) (Table 3, Fig 3).
Cardiac troponin I (cTnI) was available in 13 of 21
cats with TMT and 6 of 21 cats with HCM at presenta-
tion. Median cTnI was 2.1 [0.05–63.8] ng/mL in cats
with TMT and 1.2 [0.3–6.4] ng/mL in HCM (P = 0.2).
In 7 of 13 cats with TMT, cTnI was repeated at the
Table 1. Summary of additional clinical characteristics and laboratory parameters at initial presentation in cats
with TMT and HCM
TMT HCM P Value
Body weight (kg) 4.1 (1.9–6.2) 4.8 (2.7–7.2) 0.04
Heart rate (bpm) 180 (90–250) 190 (155–220) 0.8
Respiratory rate (breaths per minute) 64 (40–104) 58 (40–130) 0.8
Murmur (% yes) 7/21 (33%) 9/15 (60%) 0.18
Arrhythmia (% yes) 2/21 (10%) (VPCs, transient 3AVB) 3/17 (18%) (1 AF, 1 FAT, 1 VPCs) 0.64
Pulmonary edema/pleural eﬀusion/both 6/2/13 11/1/9 0.28
Hematocrit (%) 33% (15–54) 35% (24–51) 1.0
Urea (mmol/L) 12.8 (3.9–34) 11.4 (6.6–20.5) 0.27
Furosemide dose at discharge (mg/kg/d) 2.1 (0.9–5.4) 2.0 (1.4–4.0) 0.99
AF, atrial ﬁbrillation; 3AVB, third-degree atrioventricular block; FAT, focal atrial tachycardia; HCM, hypertrophic cardiomyopathy;
TMT, transient myocardial thickening; VPCs, ventricular premature complexes.
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time of LVWT normalization. Median cTnI was ele-
vated at presentation and normalized once myocardial
thickening resolved (2.1 [0.05–63.8] ng/mL versus 0.01
[0.0–0.3] ng/mL, P = .018) (reference <0.16 ng/mL).36
IgM and IgG antibodies for T. gondii and B. henselae
were measured in 4 cats with TMT. Toxoplasma was
negative in 4 of 4 and Bartonella was positive in 3 of 4
cats (IgM 1:160–640, reference <1:20; IgG 80–640,
reference <1:20), although only 1 of 3 cats was treated
for Bartonella.
Cats from both groups received various combinations
of cardiac medications at the time of CHF diagnosis.
All cats received furosemide but a greater proportion of
cats with HCM (19/21) than cats with TMT (12/21)
received medications in addition to furosemide (eg dilti-
azem, atenolol, spironolactone, pimobendan, and ACE
inhibitors, P = 0.03). Additional characteristics of the
study population are presented in Table 1.
Long-term Follow-up in Cats with TMT
After normalization of LVWT to <5.5 mm, 15 of 21
cats with TMT had a further follow-up scan up to 5 [1–
57] months later. In all cases, there was a further
decrease in LVWT from a median LVWT of 5.1 [3.8–
5.4] mm to 4.8 [2.8–5.3] mm (P = 0.02, Fig 4), while left
ventricular systolic function and left atrial size remained
normal.
Outcome Data
Congestive heart failure recurred in 1 of 21 cats with
TMT shortly after discharge, and all cats were alive at
the time of writing. CHF recurred in 15 of 21 cats with
HCM; 2 of 21 had an aortic thromboembolus; and 8 of
19 died during the study period (2 cats were lost to fol-
low-up). In 20 of 21 cats with TMT, all cardiac drugs
were discontinued at 4.6 (95% CI: 2.3–6.9) months after
discharge, as the heart was morphologically normal on
repeated echocardiographic examinations (ie normal
LVWT and LA size), and none of the cats showed clini-
cal signs thereafter. Conversely, all cats with HCM (21/
21) received medications for heart disease during the
duration of the study or until death. In 1 cat with
TMT, administration of clopidogrel and aspirin were
not stopped, even though the heart was normal on the
last echocardiographic examination, as the cat had a
previous suspicion of a thrombus on the mitral valve.
The cat was lost to follow-up.
Discussion
In this study, we describe a transient form of myocar-
dial disease in cats that mimics HCM and is associated
with CHF but has an excellent long-term prognosis.
TMT is a relatively uncommon condition that seems to
aﬀect young cats, often with a history of an antecedent
event.
The underlying pathophysiology causing the transient
ventricular wall thickening is unknown, but in view of
the fast reverse remodeling seen in our cases, myocar-
dial edema and/or transient cellular inﬁltration might
be responsible. Acute myocarditis in humans can cause
TMT that resembles HCM at initial presentation.2,7,17–
19,25,26,37–40 In these cases, the increased ventricular wall
thickness was shown to be associated with severe
myocardial interstitial edema.7,24–26 Myocardial edema
is one of the main features of the inﬂammatory
response in acute myocarditis in humans.41 Myocarditis
Table 2. Echocardiographic variables at initial presen-
tation in cats with TMT and HCM
TMT HCM P Value
LVWT (mm) 6.8 (6.0–9.7) 8.1 (6.0–12.3) 0.001
LA/Ao 1.8 (1.6–2.3) 2.4 (1.6–3.4) <0.0001
Papillary muscle
hypertrophy (% yes)
13/21 (62%) 14/21 (67%) .75
Symmetric wall
thickening (%yes)
20/21 (95%) 16/21 (76%) .18
SAM (% yes) 6/21 (29%) 6/21 (29%) 1.0
Pericardial
eﬀusion (% yes)
9/21 (43%) 8/21 (38%) 0.5
SEC (% yes) 4/21 (19%) 8/21 (38%) 0.3
LVWT, left ventricular wall thickness; LA/Ao, left atrium to
aorta ratio; SAM, systolic cranial motion; SEC, spontaneous
echocardiographic contrast.
Fig 1. Left ventricular wall thickness (LVWT) (A) and left atrial
size (LA/Ao) (B) in cats with TMT and HCM at presentation and
ﬁnal echocardiographic examination. At presentation, left ventricu-
lar walls were thicker in cats with HCM. The left atrium was lar-
ger in cats with HCM at presentation and remained dilated over
time, while it decreased over time in the TMT population. By deﬁ-
nition, the LVWT and LA/Ao decreased between the initial and
the ﬁnal echo in the TMT population, and so those two datasets
were not subjected to statistical analysis. Echo, echocardiogram;
TMT, transient myocardial thickening; HCM, hypertrophic
cardiomyopathy.
Transient Myocardial Thickening in Cats 51
is poorly described in small animals but increased
LVWT can occur with toxoplasma myocarditis,
myocarditis caused by FIV, and in eosinophilic
myocarditis.42–44 The increased LVWT can normalize if
the patient survives the acute CHF episode, as
described in a cat with toxoplasma myocarditis.42
Cats with TMT were younger than cats with HCM
(median age 1.7 versus 8 years). In people, acute
A B
C D
E F
G H
Fig 2. Right parasternal long-axis (A, B, E, F) and short-axis views (C, D, G, H) at end-diastolic frame from 2 TMT cases at initial pre-
sentation (A, C and E, G) and 7 months later (B, D and F, H). The initial severely increased left ventricular wall thickness (A, C, E, G)
and mild pericardial eﬀusion (E, G) resolved completely, with a morphologically normal heart 7 months later.
Table 3. Selective echocardiographic variables at presentation and ﬁnal echocardiographic examination in cats with
TMT and HCM
TMT HCM
Initial Echo Final Echo Initial Echo Final Echo
LVWT (mm) 6.8 (6.0–9.7) 4.8 (2.8–5.3) 8.1 (6.0–12.3) 7.9 (5.5–11)
LA/Ao 1.8 (1.6–2.3) 1.45 (1.2–1.7) 2.4 (1.6–3.4) 2.6 (2.0–5.3)
LAFS% 17 (4.3–21) 27 (15–49.6) 8.6 (0.9–17) 9 (1.7–16)
Cats with TMT showed a marked and clinically signiﬁcant decrease in LVWT and LA size over time. LA/Ao, left atrium to aorta ratio;
LVWT, left ventricular wall thickness; LAFS%, left atrial fractional shortening; LVWT, left ventricular wall thickness.
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myocarditis is most common in young individuals,45
with an average age of 10 years reported in 43 patients
from 9 diﬀerent publications (95% CI: 0.45–19.6).7,17–
19,38–40,46,47 It is possible that TMT is a form of
myocarditis as described in people. In our study, very
few cats had serological testing for Bartonella and Tox-
oplasma done which hinders any meaningful conclusion,
especially considering the high prevalence of Bartonella
seropositivity in healthy cats.48 In humans, a cause for
myocarditis is not identiﬁed in the majority of cases,
although various infectious agents, drugs (eg hypersensi-
tivity reactions), and toxins have all been reported to
cause myocarditis. Viral infections are considered to be
the most common underlying cause.7,40,45,49
The majority of cats with TMT in our study had
events preceding their presentation in CHF, and these
were more common in cats with TMT than HCM (71%
of TMT versus 29% of HCM cases). Stalis et al50de-
scribed very similar antecedent stressful events to those
observed in our TMT population in 75% of young cats
with endomyocarditis. Many cats received drugs before
presenting with TMT, and hypersensitivity drug reac-
tions are a known cause of myocarditis in humans.45,49
Alternatively, the myocardial changes observed could
potentially be a consequence of a catecholamine surge
caused by emotional or physical triggers. In humans,
catecholamines may cause toxic myocarditis in cases of
phaeocromocytoma45,51 or stress-induced (Takotsubo)
cardiomyopathy due to an exaggerated sympathetic
stimulation.52 Takotsubo cardiomyopathy is a transient
left ventricular dysfunction most frequently character-
ized by an apical “ballooning” phenotype in
people,27,52,53 but myocardial edema mimicking HCM
has also been described in Takotsubo cases, and diﬀer-
entiation from true HCM requires advanced cross-sec-
tional imaging.20–23,27,54 TMT could then potentially be
caused by an emotional or physical stress associated
with the reported antecedent events.
Cardiac troponin I was markedly elevated in most
cats with TMT where it was assessed. Blood concentra-
tion of cardiac troponins is highly sensitive and speciﬁc
for cardiac myocyte injury, and highly suggestive of
acute myocarditis when other causes of severe myocar-
dial injury have been excluded.45,55,56 However, serum
concentration of cardiac troponins is elevated in Takot-
subo patients,53 and the diﬀerentiation between these 2
entities might require cardiac magnetic resonance
(CMR) imaging.57 cTnI might potentially be useful to
diﬀerentiate TMT from HCM cases, although there is
likely to be overlap between groups. Cats with HCM
can also have substantially elevated serum cTnI concen-
trations, and some cats with TMT have normal to
mildly increased cTnI.
At presentation, cats with TMT had thinner left ven-
tricular walls than cats with HCM. If myocardial edema
is indeed the mechanism behind increased wall thickness
in TMT, it makes sense that the degree of wall thicken-
ing is limited and potentially not as extreme as seen
with left ventricular hypertrophy in HCM cases. There
was marked overlap in LVWT between the 2 groups,
and this feature cannot be used to diﬀerentiate cats with
TMT from HCM.
The cats with TMT had mild increases in left atrial
size and decreased atrial fractional shortening that nor-
malized over time. These ﬁndings suggest an acute
myocardial insult without time for the left atrium to
adapt to the increased ﬁlling pressures (ie dilate), which
caused acute increase in left atrial and pulmonary capil-
lary pressure resulting in acute pulmonary edema.
Cats with an HCM phenotype and CHF following
corticosteroid administration can show normalization of
the morphological cardiac changes over time and can
have an excellent long-term prognosis.58 This has been
postulated to be a unique form of CHF induced by cor-
ticosteroids. The clinical ﬁndings and clinical course of
cats with corticosteroid-associated CHF were very simi-
lar to our population, although older (9.3 [5.6–12.4])
Fig 3. Left atrial fractional shortening (LA%FS) in cats with
TMT (A) and HCM (B) at presentation and ﬁnal echocardio-
graphic examination. LA%FS was reduced in both groups at pre-
sentation but improved in the TMT group over time. Echo,
echocardiogram.
Fig 4. Long-term follow-up in 15 cats with TMT. Normal left
ventricular wall thickness was deﬁned as <5.5 mm (normal echo),
but all cats with serial echos showed a further decreased in wall
thickness over time. Echo, echocardiogram.
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than the cats in this study (2 [0.4–11.4] years).58 In our
study, there was no diﬀerence in the proportion of cats
receiving corticosteroids between the TMT and HCM
populations. The cats with corticosteroid-associated
CHF received these drugs for a variety of medical rea-
sons, including events that would have been classiﬁed as
antecedent stressful events in our study.
Based on our results, there were no clinical or
echocardiographic characteristics at presentation diﬀer-
entiating TMT from HCM, besides the younger age of
cats with TMT and the presence of antecedent events.
The diﬀerent progression over time may be the only
way of diﬀerentiating TMT from HCM, where cats
with TMT show reverse remodeling with normalization
of LVWT and left atrial size, while cats with HCM
show a progressive deterioration of their cardiac func-
tion. CMR imaging and endomyocardial biopsy are
both used in humans to make the diagnosis of
myocarditis, with biopsy being the gold standard.45
Transient myocardial thickening should be considered
as a diﬀerential diagnosis in cats with an HCM pheno-
type, especially in young cats with a history of an ante-
cedent event. Additionally, the perception of a poor
prognosis in symptomatic HCM (speciﬁcally with CHF)
and the need for lifelong treatment may discourage clin-
icians and owners from attempting treatment and might
result in premature euthanasia. The identiﬁcation and
description of a transient form of heart failure in cats
associated with an excellent prognosis may have an
important impact on clinical decisions made by veteri-
narians when faced with a young cat with severe CHF.
Furthermore, lifelong treatment may not be appropriate
for all cats with an initial diagnosis of decompensated
HCM.
This was a retrospective study and, as such, has some
inherent limitations. More advanced echocardiographic
parameters, such as tissue Doppler imaging and dias-
tolic function evaluation, were not systematically
assessed in our population of cats. These might have
helped distinguishing TMT from HCM cats, although
the echocardiographic variables assessed in our study
are the ones most commonly used in routine clinical
practice. Another limitation is that echocardiography
was performed at diﬀerent time points after presenta-
tion, and some cats received diuretics before the initial
echocardiographic assessment. These were cats in criti-
cal condition presented in acute left-sided CHF that
hindered detailed echocardiographic assessment.
Myocardial thickening could have therefore been caused
by pseudohypertrophy due to hypovolemia secondary
to diuretic treatment or as a result of some of the
reported antecedent events. However, we believe it is
unlikely that the increased LVWT in the cats with TMT
was pseudohypertrophy, as left atrial enlargement was
one of the inclusion criteria, and all cats showed com-
plete resolution of clinical signs with diuretic treatment.
Conclusions
We describe a transient form of myocardial disease in
cats that causes CHF but is associated with a better
prognosis than expected for cats with HCM and CHF.
TMT appears to preferentially aﬀect young cats and
often follows an antecedent event but is diﬃcult to dif-
ferentiate from HCM at presentation. The recognition
of TMT could have an important impact in daily clini-
cal cardiology, leading to clinicians and owners
attempting treatment in cases classically thought to
have a poor prognosis, and potentially avoiding prema-
ture euthanasia. Additionally, TMT might inﬂuence the
deﬁnition of HCM and design of studies of HCM in
cats.
Footnote
a SPSS 22.0.1, IBM Company, Chicago, IL
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